Targeting PRMT5 alleviates diabetic cardiomyopathy: mechanisms involve Ndufs2 R118 dimethylation-mediated complex I protection and serum PRMT5 as a biomarker
4 affiliations
- 1Department of Medicine, Division of Cardiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
- 2Department of Ultrasound, Yantian District People’s Hospital, Shenzhen, China
- 3Shenzhen University Health Science Center, Shenzhen, China
- 4Department of Cardiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Abstract
Background: Diabetic cardiomyopathy (DCM) is defined by progressive cardiac dysfunction driven by myocardial ATP depletion, where mitochondrial electron transport chain (ETC) Complex I dysfunction acts as a critical factor. Protein arginine methyltransferase 5 (PRMT5) maintains cardiac homeostasis, yet its function in DCM and association with Complex I remain elusive. This study aimed to investigate the function, key substrate, and mechanism of PRMT5 in DCM, and evaluate serum PRMT5 as a potential biomarker for DCM.
Methods: Gain- and loss-of-function experiments of PRMT5 were conducted to explore the function of PRMT5 in DCM. IP-MS proteomics and post-translational modification analysis were applied to identify the substrates of PRMT5 and their modified sites. By employing ELISA assay, serum levels of PRMT5, lactate, and lactate/pyruvate (L/P) ratio were measured in DCM patients, and the association between serum PRMT5 level and hospital readmission risk was analyzed.
Results: PRMT5 overexpression protected against DCM pathogenesis, while its knockdown or inhibition exacerbated disease progression. PRMT5 mediated symmetric di-methylation (SDMA) of Ndufs2 at R118 to prevent its ubiquitin-proteasomal degradation and preserve mitochondrial Complex I function. DCM patients had significantly lower serum PRMT5, which correlated positively with serum lactate and L/P ratio and was associated with higher hospital readmission risk.
Conclusions: Our findings unveil a novel PRMT5/Ndufs2 regulatory axis where arginine methylation maintains bioenergetic capacity of Complex I through methylation-ubiquitination crosstalk. PRMT5 shows potential as a therapeutic target and biomarker for DCM, which may aid the establishment of innovative diagnostic and treatment frameworks for DCM pending further translational validation.
Graphical Abstract:
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s10020-026-01594-2.
Related
- Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy
- Mechanisms by Which Exercise Alleviates Depressive Symptoms: The Potential Role of Short-Chain Fatty Acids
- SMYD3-catalyzed dimethylation of gasdermin D at lysine 43 promotes pyroptosis and inflammatory responses
- Targeting Mitochondrial Dysfunction with Mdivi-1 Confers Therapeutic Protection in a Mouse Model of Mustard Keratopathy
- Quorum Quenching and Quorum-Sensing Interference in Pseudomonas aeruginosa: Molecular Mechanisms, Host Protection, and Translational Barriers
BibTeX
@article{cai2026targeting,
title = {{Targeting PRMT5 alleviates diabetic cardiomyopathy: mechanisms involve Ndufs2 R118 dimethylation-mediated complex I protection and serum PRMT5 as a biomarker}},
author = {Sidong Cai and Mengqi Su and Jing Li and Yang Yu and Min Wu and Mingya Liu and Run Wang and Jie Huang and Qingxia Lai and Cong Chen and Kai-Hang Yiu},
journal = {Molecular Medicine},
year = {2026},
month = aug,
doi = {10.1186/s10020-026-01594-2},
url = {https://doi.org/10.1186/s10020-026-01594-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting PRMT5 alleviates diabetic cardiomyopathy: mechanisms involve Ndufs2 R118 dimethylation-mediated complex I protection and serum PRMT5 as a biomarker
AU - Sidong Cai
AU - Mengqi Su
AU - Jing Li
AU - Yang Yu
AU - Min Wu
AU - Mingya Liu
AU - Run Wang
AU - Jie Huang
AU - Qingxia Lai
AU - Cong Chen
AU - Kai-Hang Yiu
PY - 2026
DA - 2026/08/13
JO - Molecular Medicine
DO - 10.1186/s10020-026-01594-2
UR - https://doi.org/10.1186/s10020-026-01594-2
AB - Background: Diabetic cardiomyopathy (DCM) is defined by progressive cardiac dysfunction driven by myocardial ATP depletion, where mitochondrial electron transport chain (ETC) Complex I dysfunction acts as a critical factor. Protein arginine methyltransferase 5 (PRMT5) maintains cardiac homeostasis, yet its function in DCM and association with Complex I remain elusive. This study aimed to investigate the function, key substrate, and mechanism of PRMT5 in DCM, and evaluate serum PRMT5 as a potential biomarker for DCM. Methods: Gain- and loss-of-function experiments of PRMT5 were conducted to explore the function of PRMT5 in DCM. IP-MS proteomics and post-translational modification analysis were applied to identify the substrates of PRMT5 and their modified sites. By employing ELISA assay, serum levels of PRMT5, lactate, and lactate/pyruvate (L/P) ratio were measured in DCM patients, and the association between serum PRMT5 level and hospital readmission risk was analyzed. Results: PRMT5 overexpression protected against DCM pathogenesis, while its knockdown or inhibition exacerbated disease progression. PRMT5 mediated symmetric di-methylation (SDMA) of Ndufs2 at R118 to prevent its ubiquitin-proteasomal degradation and preserve mitochondrial Complex I function. DCM patients had significantly lower serum PRMT5, which correlated positively with serum lactate and L/P ratio and was associated with higher hospital readmission risk. Conclusions: Our findings unveil a novel PRMT5/Ndufs2 regulatory axis where arginine methylation maintains bioenergetic capacity of Complex I through methylation-ubiquitination crosstalk. PRMT5 shows potential as a therapeutic target and biomarker for DCM, which may aid the establishment of innovative diagnostic and treatment frameworks for DCM pending further translational validation. Graphical Abstract: Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s10020-026-01594-2.
SN - 1076-1551
SN - 1528-3658
ER -